Runs an e-commerce catalog selling laboratory reagents and fine chemicals to Chinese research labs.
Runs an e-commerce catalog selling laboratory reagents and fine chemicals to Chinese research labs.
Sells a very broad catalogue of reagents and chemicals through its website and marketplaces, with quick delivery to research labs, so orders are small but frequent and rely on repeat buyers. Products are a mix of items it makes itself and others it resells, and the own-made items carry better margins.
In one line: A Chinese Sigma-Aldrich (lab reagent catalog/e-commerce).
Moat: narrow (distribution, brand, installed base). Broad reagent catalog and e-commerce platform create convenience-driven repeat buying.
Headquarters: Shanghai, China · Founded: 2009 · Employees: 926
Size Shanghai Aladdin Biochemical Technology (688179.SS) is a China Health Care company (Medical Specialties) with a market value of $736M, the 2780th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥13.70 on 18 Nov 2026.
Performance Over six months the shares fell 37.4%, against -13.5% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 39.1% over the last twelve months (peer median +5.9%); the operating margin is 24.4% (peer median 11.4%).
Valuation It trades at 27.4× forward earnings against a peer median of 19.8× (4th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +24%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.3 points above its cost of capital (10.5% WACC).
Next results Next results expected around 21 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥829M | CN¥690M | CN¥530M | CN¥402M | CN¥377M |
| Revenue growth | — | +30% | +32% | +7% | — |
| Gross profit | CN¥550M | CN¥405M | CN¥305M | CN¥216M | CN¥202M |
| EBITDA | n/a | CN¥215M | CN¥170M | CN¥118M | CN¥115M |
| Net income | CN¥143M | CN¥102M | CN¥98.8M | CN¥85.8M | CN¥92.8M |
| Free cash flow | CN¥197M | CN¥356M | CN¥117M | CN¥10.1M | -CN¥105M |
| Capital expenditure | CN¥6.22M | CN¥49.0M | CN¥35.5M | CN¥45.7M | CN¥62.0M |
| Total debt | CN¥420M | CN¥773M | CN¥443M | CN¥358M | CN¥342M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai Aladdin Biochemical Technology 688179.SS | $736M | -37% | +39% | 24% | 27.4× | 17.1% |
| Merck KGaA MRK.DE | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% |
| Bide Pharmatech 688073.SS | $801M | +10% | +10% | 19% | 24.3× | 13.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688179.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.7% | -8.5% | 3rd lowest of 21 |
| 6-month return | -37.4% | -13.5% | 3rd lowest of 21 |
| Distance from 52-week high | -56.7% | -37.6% | 3rd lowest of 21 |
| Revenue growth (TTM) | +39.1% | +5.9% | 4th highest of 21 |
| Operating margin | 24.4% | 11.4% | 2nd highest of 21 |
| Forward P/E | 27.4× | 19.8× | 4th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 17.1% | 5.9% | 5th most demanding of 15 |
| Growth delivered (Del g) | +24.2% | +12.8% | 3rd highest of 15 |
| Hurdle (Req g minus delivered) | -7.2 pp | -11.1 pp | 7th most demanding of 15 |
| ROIC minus cost of capital | +1.3 pp | +1.3 pp | 11th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $736M | -37% | +39% | 24% | 27.4× | 17.1% | +24.2% |
| BMC Medical 301367.SZ | China | $737M | -17% | +37% | 17% | 18.7× | -1.5% | +15.6% |
| Beijing Aerospace Changfeng 600855.SS | China | $738M | -44% | -10% | -19% | n/a | n/a | n/a |
| InMode INMD | United States | $741M | -8% | +2% | 18% | 9.8× | -10.8% | +12.4% |
| Shanghai Runda Medical Technology 603108.SS | China | $744M | -36% | -12% | -2% | 20.5× | 20.3% | -0.2% |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $744M | -3% | +12% | 18% | 16.2× | -1.9% | +11.8% |
| Allmed Medical Products 002950.SZ | China | $747M | -32% | +14% | 8% | n/a | n/a | n/a |
| Caina Technology 301122.SZ | China | $721M | +36% | +61% | 0% | 55.4× | n/a | n/a |
| Sino Medical Sciences Technology 688108.SS | China | $753M | -41% | +22% | 19% | 60.0× | 27.9% | +9.9% |
| Maccura Biotechnology 300463.SZ | China | $756M | -18% | -1% | -4% | 421.0× | 7.9% | -10.2% |
| Doctorglasses Chain 300622.SZ | China | $710M | -22% | +6% | 14% | 22.8× | -3.4% | +15.7% |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 14.4× | 3.8% | +105.8% |
| SWS Hemodialysis Care 688410.SS | China | $706M | -11% | +31% | 19% | 23.5× | 16.2% | +25.9% |
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 19.9× | n/a | n/a |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 19.8× | 9.6% | +15.5% |
| Japan Lifeline 7575.T | Japan | $703M | +34% | +6% | 19% | 14.5× | -9.5% | +2.9% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | n/a | n/a | n/a |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $700M | -25% | +35% | 21% | 15.9× | -3.3% | +23.5% |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 11.5× | 21.3% | +13.2% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $697M | +148% | -14% | 3% | n/a | 31.8% | -0.6% |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | n/a | n/a | n/a |